Statera Biopharma Inc Fka Cytocom Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Statera Biopharma Inc Fka Cytocom Inc (STAB) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Statera Biopharma Inc Fka Cytocom Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 4M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-27.3% annualized vs trailing 12 months).
- Peer revenue share: Statera Biopharma Inc Fka Cytocom Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
STAB Sales vs. its Competitors, Q3 2022
Statera Biopharma Inc Fka Cytocom Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs 183.5% for Statera Biopharma Inc Fka Cytocom Inc. Statera Biopharma Inc Fka Cytocom Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.